Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
Hepion Pharmaceuticals completed its acquisition of Gravitas Life Sciences on October 6, 2026, adding a clinical-stage lead program GV104 (nalmefene buccal film for opioid prophylaxis) and near-clinical GV023 (oral infliximab). The Board appointed former GLS CEO Sireesh Appajosyula as Hepion's CEO and former interim CEO Gary Stetz as CFO on October 9, 2026. GV104's path to a 505(b)(2) NDA relies on manufacturing completion rather than new clinical studies, per FDA feedback; Hepion plans commercial-scale registration batches beginning in 2027.
Key figures
- Deal Value Usd
- 0
- Gv104 dose
- 16 mg nalmefene buccal film
- Closing date
- October 6, 2026
- Gv104 bioavailability
- 45.9%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.